Article
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Haematologica - 1 Aug 2014
Hubmann Max, Köhnke Thomas, Hoster Eva, Schneider Stephanie, Dufour Annika, Zellmeier Evelyn, Fiegl Michael, Braess Jan, Bohlander Stefan K, Subklewe Marion, Sauerland Maria-Cristina, Berdel Wolfgang E, Büchner Thomas, Wörmann Bernhard, Hiddemann Wolfgang, Spiekermann Karsten
Abstract excerpt
Monitoring minimal residual disease is an important way to identify patients with acute myeloid leukemia at high risk of relapse. In this study we investigated the prognostic potential of minimal residual disease monitoring by quantitative real-time polymerase chain reaction analysis of NPM1 mutations in patients treated in the AMLCG 1999, 2004 and 2008 trials. Minimal residual disease was monitored - in aplasia,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.